Search

Kadsura coccinea roots are a traditional folk medicine used to treat gastrointestinal diseases. In recent years, research on K. coccinea has predominantly focused on the analysis of chemical composition and screening for activity, but there is a scarcity of studies that employ mass spectrometry to analyze Kadsura coccinea roots. This study aimed to characterize the chemical composition of K. coccinea roots and explore the pharmacological mechanisms with network pharmacology. Cell assay and Western blot analysis were used to verify the pharmacological mechanism of the main compounds in K. coccinea roots. UPLC-Q-Exactive Orbitrap/MS was used for chemical analysis of K. coccinea roots, and the compounds were identified by employing diagnostic product ions, fragmentation patterns, ChemSpider, and in-house databases. Network pharmacology was employed to estimate the pathways related to pharmacological mechanisms. In addition, MTT assay was conducted to determine the inhibitory activity of colon cancer cell lines, and their apoptotic abilities were evaluated by flow cytometry and Western blot. The UPLC-Q-Exactive Orbitrap/MS identified a total of 54 compounds in K. coccinea roots. The 54 compounds were subjected to network pharmacology analysis, exploring the pharmacological action of the main components of K. coccinea roots. The common targets between the compounds and colon cancer comprised 2009 GO biological process items and 186 KEGG signal pathways. Flow cytometry indicated that treatments with 20 μM of the above-named compounds resulted in an apoptosis rate of 16.6%, 79.7%, and 22.2% in HCT-116 cells, respectively. Meanwhile, Western blot analysis confirmed that the compounds promoted the expression of Bax and Caspase-3 level expression. The findings demonstrated that K. coccinea roots can treat colon cancer through multiple components, targets, and pathways. This study revealed the effective components and molecular mechanisms of K. coccinea , which were preliminarily verified using in vitro experiments. [Display omitted] [ABSTRACT FROM AUTHOR]

The objective of this study is to investigate the association between the Systemic Immune-Inflammation Index (SII) and cataracts. This cross-sectional study analyzed data from the 2005-2008 NHANES to examine the relationship between the SII and cataract prevalence. Covariates included age, race/ethnicity, gender, education level, marital status, Body Mass Index (BMI), smoking, alcohol consumption, hypertension, hyperlipidemia, and diabetes. Multivariable logistic regression was used to assess the association, while spline curve fitting explored potential non-linear relationships. Threshold analysis identified critical inflection points. To address age-related bias, Propensity Score Matching (PSM) was performed, aligning cataract patients with comparable non-cataract individuals for further evaluation. Our study included 3,623 participants, of whom 730 (20.15%) were diagnosed with cataracts. After adjusting for all covariates, multivariable logistic regression analysis demonstrated that elevated levels of the SII were significantly associated with increased odds of cataracts (Model1: OR = 1.56; 95%CI [1.33-1.85]; Model2: OR = 1.55; 95%CI [1.32-1.84]; Model3: OR = 1.57; 95%CI [1.33-1.86]). In the spline curve fitting model, the relationship between ln-SII and cataract prevalence was non-linear (P < 0.001), with a critical inflection point identified at an SII of 428.38. SII levels remained significantly associated with cataract prevalence following PSM adjustments (Model 1: OR = 1.48; 95% CI [1.21-1.80]; Model 2: OR = 1.48; 95% CI [1.21-1.80]; Model 3: OR = 1.46; 95% CI [1.20-1.78]). Elevated SII levels are associated with a higher prevalence of cataracts, underscoring the pivotal role of systemic inflammation in cataract development. These findings indicate that SII could serve as a valuable biomarker for assessing cataract risk, further emphasizing the significance of managing systemic inflammation as a potential strategy for cataract prevention., Competing Interests: Competing interests: The authors declare no competing interests. Ethical considerations and informed consent: Considering that the NHANES database is publicly accessible, and patient records are anonymous and de-identified, it does not involve informed consent or ethical approval., (© 2024. The Author(s).)